MCL Literature Feed

A phase 1 study in Chinese relapsed/refractory B-cell NHL patients establishes the recommended dose of the HDAC inhibitor abexinostat (80 mg BID) with promising activity, supporting further development.

This preclinical study identifies CEACAM1 as a novel activator of B-cell receptor signaling by recruiting SYK, revealing a new potential therapeutic target and mechanism of resistance to BCR inhibitors.

This myeloma review outlines strategies to overcome proteasome inhibitor resistance by targeting other proteostasis pathways, providing a rationale for exploring similar combinations in relapsed/refractory MCL.

The novel circular RNA-based biomarker, circSCORE, demonstrates prognostic value in relapsed/refractory MCL, offering a new tool for risk stratification in this high-risk patient population.

A novel single-cell method integrating biophysical properties with transcriptomics identifies distinct MCL subpopulations, suggesting cell mechanics could be a new biomarker for tumor heterogeneity and therapeutic resistance.

In a modern Canadian cohort, allogeneic transplant for relapsed/refractory MCL achieved a 5-year overall survival of 68.1%, confirming its ongoing relevance as a curative-intent therapy.

This preclinical study of a selective immunoproteasome inhibitor in ALL suggests a potential future strategy for MCL to achieve efficacy similar to bortezomib with potentially less off-target toxicity.

This retrospective series of six patients establishes that esophageal multiple lymphomatous polyposis in MCL signifies high tumor burden and a very poor prognosis, with median survival under two years.

This study compares bendamustine-rituximab (BR) versus R-CHOP as initial therapy for transplant-ineligible MCL patients, providing evidence to guide frontline treatment selection in this common clinical setting.

A rare B-ALL subtype with a MEF2D::BCL9 fusion can mimic blastoid MCL by co-expressing CD5 and SOX11, highlighting a critical diagnostic pitfall requiring molecular confirmation.

Overexpression of IL-16 drives BTKi resistance via the CD9/NF-κB/AKT axis in MCL models, presenting a novel therapeutic target to overcome treatment failure and restore drug sensitivity.

In older relapsed/refractory MCL patients, brexucabtagene autoleucel offers superior 1-year overall survival and lower non-relapse mortality versus allogeneic transplant, though long-term outcomes are similar, guiding treatment selection.

In frontline MCL, pre-treatment ctDNA levels and TP53 mutations predict poor survival, while post-treatment ctDNA clearance identifies patients with favorable outcomes, establishing its clinical utility for prognosis.

This review provides a practical guide for differentiating aggressive B-cell lymphomas, including mantle cell lymphoma, emphasizing the integration of morphology, immunohistochemistry, and molecular testing for accurate diagnosis and classification.

This review summarizes favorable outcomes for CAR-T and bispecific antibodies in relapsed/refractory MCL, detailing their integration into the treatment paradigm for patients with poor prognoses post-BTKi.

High p62 expression predicts poor survival in MCL by upregulating CCND1 transcription via Nrf2, identifying p62 as a novel prognostic biomarker and potential non-BTK/BCL2 therapeutic target.

This phase 2 trial shows ibrutinib is effective in high-risk, previously untreated smoldering MCL, suggesting early intervention with a BTKi can delay progression in this traditionally observed population.

A novel single-cell genomic research model tracks MCL clonal evolution, providing a high-resolution tool to dissect mechanisms of therapeutic resistance and identify potential new targets.

This review synthesizes mechanisms of BTKi resistance and highlights next-generation strategies like noncovalent BTKi and PROTACs to overcome this critical challenge in relapsed/refractory MCL.

NGS-detected TP53 mutations are a major clinical risk factor, enabling precise patient stratification to guide initial therapy selection and identify candidates for novel agents.

A novel high-performance liquid chromatography-ultraviolet (HPLC-UV) assay was developed to measure pirtobrutinib levels, enabling therapeutic drug monitoring to potentially optimize dosing in MCL patients.

The chemotherapy-free triplet of acalabrutinib (BTKi), umbralisib (PI3Ki), and ublituximab (anti-CD20) achieved high response and MRD-negativity rates in untreated MCL, presenting a novel frontline option.

This real-world study from Colombia confirms the prognostic value of the MIPI score and the survival benefit of autologous stem cell transplant in a Latin American MCL cohort.

This review provides a practical guide for clinicians on the approved indications and real-world application of anti-CD19 CAR-T cell therapy for mantle cell lymphoma.

Optical genome mapping reveals diverse cryptic CCND1/2 rearrangements in ~10% of MCLs lacking the classic t(11;14), improving diagnosis and identifying high genomic complexity associated with poor outcomes.

This case report of primary colonic MCL presenting with intussusception highlights surgery's crucial role in diagnosis and managing complications for rare, localized extranodal disease before systemic therapy.

Optical genome mapping detects additional clinically significant genomic aberrations in 8% of mantle cell lymphoma cases compared to standard cytogenetics, potentially improving risk stratification.

This large pooled analysis of 1280 trial patients validates progression within 24 months (POD24) as a robust indicator of poor survival, with rituximab maintenance reducing this risk.

In young, fit MCL patients undergoing frontline autotransplant, large clonal hematopoiesis clones (VAF ≥10%) at baseline are a novel biomarker for worse progression-free and overall survival.

The novel TBL1X inhibitor tegavivint induces DNA damage and synergizes with PARP inhibitors in preclinical MCL models, establishing TBL1X as a new therapeutic target for genomic instability.